Roche launches Ocrevus for treatment of multiple sclerosis in India

Patients on Ocrevus have the highest persistence and superior adherence to treatment because of its twice-yearly (once every six months) dosing which is preferable for most patients compared to more frequent (monthly) injections. ~80 per cent of patients adhered to the twice-yearly dosing of Ocrevus after their second year of treatment compared with other DMTs.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/DGZHwEa
via